Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
Insider transactions by Arcus Biosciences (RCUS): The company's Chief Operating Officer exercised stock options and sold a total of 50,292 shares across two dates, 10/06/2025 and 10/08/2025. The exercises used options with a $1.2276 exercise price, adding 50,292 underlying shares to the reporting pool. Sales were executed at weighted-average prices of $14.5441 and $15.0458, and the filings state these transactions were made pursuant to a Rule 10b5-1 trading plan. Following the transactions the reporting person beneficially owned 214,232 shares, which includes 863 shares bought via the employee stock purchase plan on 05/30/2025. The options exercised were fully vested and exercisable, with expiration dates noted as 03/14/2027.
Arcus Biosciences, Inc. filed a Form 144 reporting a proposed sale of 100,583 shares of common stock through J.P. Morgan Securities LLC on 10/06/2025. The filing shows the shares were acquired and paid for on 10/06/2025 via a stock option exercise with payment in cash. The aggregate market value listed for the shares to be sold is 1,342,783 and the total shares outstanding are 106,430,976, which implies the block represents roughly 0.095% of outstanding shares. No other sales in the past three months were reported and no seller name is disclosed in the public sections of the form.
Arcus Biosciences reported updated Phase 1/1b ARC-20 monotherapy data for casdatifan in metastatic clear cell renal cell carcinoma and outlined new immunology and inflammation programs. Across four dosing cohorts (total n=121 in the pooled analysis), pooled median progression-free survival was 12.2 months, with a 12‑month PFS rate of 50% and a confirmed objective response rate of 31%. The pooled disease control rate was 81%, and median time to response was about three months.
In the safety-evaluable population (n=127), 31% of patients experienced serious treatment-emergent adverse events, while Grade ≥3 treatment-emergent events related to casdatifan occurred in 49% of patients, most commonly anemia and hypoxia. Arcus stated that no unexpected safety signals were observed and that casdatifan had an acceptable and manageable safety profile. The company also highlighted several advanced discovery and preclinical programs in immunology and inflammation, and expects to initiate one or more clinical studies from these programs in 2026.
Arcus Biosciences (RCUS) insider sale by Chief Accounting Officer. The reporting person sold 2,831 shares of Arcus common stock on 09/29/2025 at $13.00 per share, leaving beneficial ownership of 27,363 shares after the transaction. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted on June 6, 2025. The filing was executed by an attorney-in-fact on 09/30/2025. This report discloses a planned, executed disposition by a senior financial officer that reduced their holdings by approximately 9.4% of their pre-sale position.
Arcus Biosciences (RCUS) Form 144 summary: The notice reports a proposed sale of 2,831 common shares through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $36,350.04. The shares were acquired as restricted stock units on 12/15/2024 and the filing shows the acquisition and payment date as 12/15/2024. The form also discloses a prior sale during the past three months: a 10b5-1 sale by Alexander Azoy of 1,579 shares on 09/05/2025 for gross proceeds of $18,758.05. The filer certifies they are not aware of undisclosed material adverse information and notes Rule 10b5-1 plan considerations where applicable.
Arcus Biosciences insider sale by Chief Accounting Officer. Alexander Azoy, listed as Chief Accounting Officer, reported a sale of 1,579 shares of Arcus Biosciences (RCUS) on 09/05/2025. The filing shows these shares were originally purchased on 05/30/2025 through the company Employee Stock Purchase Plan and were sold under a Rule 10b5-1 trading plan adopted 06/06/2025. The weighted-average sale price reported is $11.8797, with individual sale prices ranging from $11.55 to $12.22. After the reported sale, the reporting person beneficially owned 30,194 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Arcus Biosciences, Inc. (RCUS) notice reports a proposed sale of 1,579 common shares acquired under an Employee Stock Purchase Plan on 05/31/2025. The shares have an aggregate market value of $18,253.24 and the issuer has 106,430,976 shares outstanding. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 09/05/2025. Payment for the acquisition was cash. The filer states there were no securities sold by the person in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.